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while total costs incurred by this population sample were 3,774,256RSD. Highest 
unit utilization of services belongs to conservative dentistry (31.9%), oral surgery 
(19.5%) and radiology (17.4%), while highest value based turnover belongs to implan-
tology 90,765.33±43,012.31RSD, orthodontics 77,361.82±73,123.92RSD and pros-
thetics 60873.89±26788.87RSD. Most frequently treated diagnosis was tooth decay 
(33.8% unit services provided), pulpitis (11.2%) and impacted teeth (8.5%), while 
most expensive to treat were anomalies of tooth position (70,998.33±73122.73RSD), 
abnormalities of size and form of teeth (55,662.50±77,304.45RSD) and loss of teeth 
due to accident, extraction or local periodontal disease (36,835.35±37,128.28RSD). 
ConClusions: Although range of dental medical costs currently falls behind EU 
average, Serbia’s emerging economy is likely to expand in the long run while market 
demand for dental services will grow. Due to threatened financial sustainability of 
current health insurance patterns in Eastern Europe, getting acquainted with true 
size and structure of dental care costs might essentially support informed decision 
making in future.
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objeCtives: To assess the cost-effectiveness of Ustekinumab (UST) com-
pared with Etanercept (ETN) in Costa Rica, in patients with Moderate to Severe 
Psoriasis. Methods: A cohort simulation Markov Model was developed based on 
response rates for UST and ETN [Psoriasis Area Severity Index (PASI) ]. The time 
frame was 10 years. The perspective was that of the Public System of Health of 
Costa Rica. The health outcome of interest was Quality Adjusted Life Years (QALYs). 
Efficacy data was taken from the ACCEPT clinical trial; this phase III clinical trial 
directly compares UST and ETN, what strongly supports the efficacy data that is 
used in the model. Utilities for health states were taken from published studies. 
The base year was 2013. All costs are presented in Costa Rican currency (Colones – 
CRC). Costs and outcomes were discounted at 3.5%. Probabilistic sensitivity analysis 
(PSA) was conducted to assess uncertainty around the parameters. Results: UST 
resulted in 3.85 QALYs and ETN in 3.58, per patient, respectively. Mean total costs 
per patient were: CRC 8.441.031 for UST and CRC 5.401.222 for ETN. UST resulted 
both more costly and more effective than ETN. The Incremental Cost Effectiveness 
Ratio comparing UST and ETN was 11.142.470 per QALY Gained. According to the 
classification of the World Health Organization (WHO), the acceptable threshold for 
QALY Gained for Costa Rica is CRC 14.140.792 (3 times the Gross Domestic Product 
per capita). The results of the probabilistic sensitivity analysis showed that, at the 
threshold suggested by the WHO, the probability of UST of being cost effective, 
compared with ETN is around 70%. ConClusions: UST can be considered cost 
effective when compared to ETN, according to the threshold suggested by the WHO, 
in patients with moderate to severe Psoriasis, from the perspective of the Public 
System of Health of Costa Rica.
PSS23
CoSt-EffECtivEnESS of rAnibizUmAb on PAtiEntS With diffUSE 
diAbEtiC mACUlAr EdEmA Within thE PUbliC mExiCAn hEAlth CArE 
SyStEm
Ruiz Miranda C.I., Ubiarco Lopez V.
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objeCtives: To perform a cost-effectiveness analysis of Ranibizumab plus laser 
photocoagulation vs monotherapy with laser photocoagulation in patients with 
diffuse Diabetic Macular Edema (DME). Methods: A Markov model was designed 
to analyze laser Photocoagulation vs laser Photocoagulation plus Ranibizumab. 
Transition probabilities were obtained from RESTORE. The base patient was a dia-
betic with 53 years presenting DME, according to Mexican context. General mortality 
rates were elicited locally from CONAPO*. A panel Delphi was performed to get use 
of resources locally. The time horizon was 5, 7, and 10 (lifetime) years according 
to life expectancy from ENSANUT** 2013, discount rate 5%. The outcome was life 
years without visual impairment. The cost values were from Guidelines for the 
Exchange of Services in the Health Sector. Probabilistic sensitivity analysis (PSA) was 
performed using Monte Carlo technique. Results: Incremental Cost Effectiveness 
Ratios of the combination versus the monotherapy were: $5,019.57, $2,375.62 and 
$622.67 USD per life year without visual impairment in a time horizon of 5, 7 years 
and lifetime. Cost effectiveness curve showed Ranibizumab be a cost effective 
option at 98.7% vs monotherapy before reaching the GDP per capita. ConClusions: 
Ranibizumab demonstrated to be a more cost-effectiveness alternative than mono-
therapy with laser photocoagulation. These results show the possibility of achiev-
ing potential clinical benefit with Ranibizumab in patients suffering from loss of 
vision. *CONAPO National Council of Population **ENSANUT National Health and 
Nutrition Survey
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objeCtives: Like other North African countries, Tunisia has a substantial burden of 
pneumococcal disease, with high resistance to antibiotics. The Tunisian population 
remains largely unprotected in the absence of a national immunization program 
(NIP). Methods: A decision-analytic model was developed to evaluate the potential 
outcomes and costs of the PCV13-based NIP compared to no vaccination. The model 
estimates bacteremia and meningitis (jointly IPD), all-cause community acquired 
pneumonia (CAP), and all-cause otitis media (OM). The demographics and disease 
and a higher percentage TBSA burned also corresponded to significantly higher 
costs. ConClusions: Mean total costs of burn care in the first three months post 
injury were estimated at € 24,246 and depended on age, etiology and TBSA. Mean 
total costs in our population probably apply for other high-income countries as well, 
although we should realize that patients with burn injuries are diverse and repre-
sent a broad range of total costs. To reduce costs of burn care, future intervention 
studies should focus on reducing length of stay and enabling an early return to work.
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objeCtives: Aims The aim of this study is to estimate the prevalence of blind-
ness in the Republic of Ireland and estimate the financial and economic cost of 
blindness between 2010 and 2020. Methods: The prevalence of blindness was 
based on the National Council for the Blind of Ireland blind register and adjusted 
for under registration found in previous literature. The financial cost of blind-
ness was based on the sum of total direct and indirect health care costs (direct 
health care costs due to blindness, cost of depression due to blindness, cost of 
injurious falls due to blindness) and non-health care costs (productivity losses, 
informal care and deadweight welfare loss). Where possible, methods adopted 
reflect those used elsewhere in the literature. Results: The total financial cost 
of blindness in the ROI is estimated to have been € 276. million in 2010. This is 
projected to increase by 32.6% to € 367 million in 2020 if current trends in disease 
burden continue. The total economic cost of blindness in the ROI is estimated to 
be € 809 million in 2010 and is predicted to increase to over € 1.1 billion in 2020 
based on current trends. ConClusions: A significant proportion of blindness 
can be avoided through the implementation of existing technologies by the 
health service. However a significant portion (98.04%) of the burden of illness 
falls beyond the health service (primarily to the Department of Social Protection 
and the Department of Finance) and may serve to reducethe priority of policies 
aimed at avoiding blindness that might otherwise be received.
PSS20
CoSt-of-illnESS StUdy of SEnilE CAtArACt in thE CzECh rEPUbliC
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Cost-of-illness study of senile cataract in the Czech RepublicIlona Kruntorádová, 
Klára Kruntorádová, Vladimír Rogalewicz, Miroslav Barták. objeCtives: In the 
Czech Republic, 7% of patients with senile cataract are indicated for surgery each 
year, which means ten thousand of interventions annually. The aim of this study 
is to quantify direct costs in relation to the implanted intraocular lens type from 
both the public health insurance perspective and the patient’s perspective. The 
senile cataract surgery with monofocal IOL is covered by public health insur-
ance. Methods: Direct costs were calculated through a panel of experts that pro-
vided expert opinions, taking into account consumption of paid medical services 
provided to patients. The panel consisted of 6 experts (4 physicians from eye clinics, 
2 physicians from outpatient departments). Patient´s costs were obtained through 
a patient questionnaire asking the direct (out-of-pocket) expenses associated with 
the cataract. The study covered a cohort of 200 patients with senile cataract in 
non-productive age (65+). Data were collected from 4 clinics performing cataract 
surgery. Results: The structure of direct costs associated with senile cataract, 
its surgery, and treatment of possible complications has been specified. Direct 
costs of senile cataract surgery from the perspective of public health insurance 
are CZK24900 (»EUR907) per person. Patient´s direct costs are lower for monofocal 
lenses than for multifocal ones. Patients’ costs for an IOL and the related treatment 
reach up to CZK35000 (»EUR1275), out of pocket expenses after treatment average 
out at CZK4450 (»EUR162). ConClusions: Due to absence of laws governing medi-
cal care premium services and the age of patients, monofocal IOLs are implanted 
predominantly. As a consequence, up to CZK 30 million (»EUR 1 1 million) are saved 
on the public health insurance budget annually. Patients´ expenses for implanting 
multifocal lenses are offset by savings due to unrealized spending for eyeglasses 
and related medical care in the course of time.
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objeCtives: Dental medical care bears particular financial burden for Eastern 
European transitional economies due to its lack of insurance coverage in most 
countries of the region and almost complete out-of-pocket payments by citizens. 
This study estimates real costs of these services in the field and describe resource 
use patterns and differentials across clinical dentistry branches, ICD-10 diagnostic 
groups, and across particular medical services. Methods: In a case-series design 
prospective cost-comparison study has been conducted from the perspective of 
the patient. Sample size was 752 complete episodes of treatment, selected ran-
domly in 2012/2013 throughout an array of several specialist state-owned (university 
associated) and private-owned dental clinics in upper-middle income Serbia. All 
direct medical costs of dental care were taken into account. Costs were expressed 
in national currency Republican Serbian Dinar (RSD). Results: Mean total direct 
medical costs of dental care were 5,018.96±17,109.61RSD per single dentist visit 
